ALLO Earnings Prediction
The chart below shows how ALLO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALLO sees a +1.15% change in stock price 10 days leading up to the earnings, and a -5.93% change 10 days following the report. On the earnings day itself, the stock moves by -0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
ALLO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
-100.00%
--
Gross Margin
--
--
--
Operating Margin
-895418.18%
212.71%
44.90%
Net Margin
-898413.64%
217.32%
50.47%
EPS
-0.32
-13.51%
-8.57%
No Data Available
ALLO Earnings Analysis
Allogene Therapeutics, Inc. Common Stock Corporation (ALLO.O) Earnings Conference Call
Positive
Celemab-Cel Therapy Progress: In the third quarter, Allogene achieved significant progress in advancing the pivotal Phase II ALPHA 3 trial of its celemab-cel therapy for large B-cell lymphoma, marking a crucial step towards redefining treatment options.
Renal Cell Carcinoma Efficacy: The Phase 1 TRAVERS trial for renal cell carcinoma demonstrated unprecedented efficacy, achieving a confirmed response rate of 33% and an overall response rate of 50% in heavily pre-treated patients with high CD70 expression.
Strong Cash Position: Allogene's cash balance at the end of Q3 2024 was $403.4 million, providing a strong financial foundation to support ongoing research and development efforts.
R&D Expenses Overview: Research and development expenses for Q3 2024 were $44.7 million, reflecting a commitment to advancing innovative therapies, including $5.6 million in non-cash, stock-based compensation.
Projected Cash Burn: The company continues to expect a cash burn of approximately $200 million for 2024, indicating a strategic investment in future growth and development.
Negative
R&D Expenses Overview: Q3 2024 research and development expenses were $44.7 million, which includes $5.6 million in expenses associated with non-cash, stock-based compensation.
Q3 2024 Net Loss: For Q3 2024, our net loss was $66.3 million or $0.32 per share, including non-cash, stock-based compensation expense of $13.4 million and $10.7 million in non-cash impairment of long-lived asset expense.
Projected Cash Burn: For 2024, we continue to expect a cash burn of approximately $200 million.
2024 Operating Expense Forecast: We continue to expect fully year 2024 GAAP operating expenses to be approximately $300 million, which includes estimated non-cash, stock-based compensation expense of approximately $60 million.
Cash Balance and Runway: Our cash balance as of the end of the third quarter 2024 was $403.4 million in cash, cash equivalents, and investments, and our cash runway continues to extend into the second half of 2026.
ALLO FAQs
How does ALLO typically perform around its earnings report dates?
Is Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ALLO Earning Call Sentiment
Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ALLO.O
2.77%Positive
The earnings call presents a mixed picture. Basic financial performance shows a net loss, but a strong cash position extends the runway to 2026. Product development is progressing, but complexity in clinical trials could delay outcomes. Market strategy and shareholder plans are unclear. The Q&A reveals positive sentiment on safety and trial enthusiasm, but management's evasive responses on data thresholds raise concerns. Overall, the sentiment balances out to neutral, with no strong catalysts for significant price movement in the short term.
